Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Actinium Pharmaceuticals Inc ATNM

Healthcare Biotechnology
Actinium Pharmaceuticals, Inc. is a late-stage biopharmaceutical company. The Company is engaged in developing targeted radiotherapies to improve survival for people who have failed existing oncology therapies. The Company’s advanced pipeline candidates include Iomab-B (pre-BLA & MAA (EU)) and Actimab-A. Iomab-B is an induction and conditioning agent prior to bone marrow transplant. Actimab-A... see more

Recent & Breaking News (NYSEAM:ATNM)

Actinium Pharmaceuticals to Present at 9th Annual Biotech Showcase™ 2017 Conference 

GlobeNewswire January 10, 2017

Actinium Pharmaceuticals to Present at 9th Annual Biotech Showcase™ 2017 Conference

GlobeNewswire January 4, 2017

Actinium Pharmaceuticals Appoints Jeannine Larrieux, Ph.D. as Director of Analytical Development to Support BLA and IND Enabling Analytical Studies for Current and Future Clinical Programs

GlobeNewswire December 19, 2016

Actinium Pharmaceuticals Announces Submission of EU Orphan Designation Application for Actimab-A

GlobeNewswire December 13, 2016

Actinium to Sponsor Upcoming Blood & Marrow Transplant Information Network Webinar Focused on Stem Cell Transplants for Patients with AML

GlobeNewswire December 12, 2016

Actinium Highlights Results from Phase 1 Clinical Trial of Actimab-A at 58th American Society of Hematology Annual Meeting

GlobeNewswire December 5, 2016

Actinium Further Strengthens Clinical Development Team with Senior Hire to Support Later-Stage Clinical Trials

GlobeNewswire November 29, 2016

Actinium Issues Letter to Shareholders Highlighting 2016 Accomplishments and Anticipated Milestones for 2017

GlobeNewswire November 22, 2016

Actinium Pharmaceuticals to Present at LD Micro Main Event Investor Conference

GlobeNewswire November 21, 2016

Actinium Announces Notice of Allowance for U.S. Patent Related to Actimab-A

GlobeNewswire November 14, 2016

Research Reports Initiation on Healthcare Stocks -- Humana, Aerie Pharma, Molina Healthcare, and Actinium Pharma

PR Newswire November 4, 2016

Actinium Pharmaceuticals Announces Key Hire in Clinical Supply Chain Organization as Company Expands To Accommodate Continued Growth

GlobeNewswire October 31, 2016

Actinium Pharmaceuticals Announces New Hires As Supply Chain Organization Expands To Accommodate Growth

GlobeNewswire October 26, 2016

Actinium Pharmaceuticals Initiates Pursuit of Scientific Advice for Iomab-B from the European Medicines Agency

GlobeNewswire October 25, 2016

Actinium Announces Acceptance of Actimab-A Data for Poster Presentation at American Society of Hematology Annual Meeting

GlobeNewswire October 19, 2016

Actinium Pharmaceuticals Granted Orphan Designation from the European Medicines Agency for Iomab-B

GlobeNewswire October 18, 2016

Actinium Announces Closing of Public Offering of Common Stock

GlobeNewswire October 4, 2016

Mid-Afternoon Market Update: Dow Falls Over 200 Points; Catabasis Shares Spike Higher

Benzinga.com  September 29, 2016

12 Biggest Mid-Day Losers For Thursday

Benzinga.com  September 29, 2016

Mid-Day Market Update: Crude Oil Rises Over 2%; Intra-Cellular Therapies Shares Slide

Benzinga.com  September 29, 2016